We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Teva, Natco Announce First U.S. Generics of Bristol Myers Squibb’s Cancer Drug Revlimid
Teva, Natco Announce First U.S. Generics of Bristol Myers Squibb’s Cancer Drug Revlimid
Teva Pharmaceuticals and Natco Pharma have announced the launch of the first generic versions of Revlimid (lenalidomide) in the U.S., a move that will take a bite out of Bristol Myers Squibb’s (BMS) profit from the blockbuster blood cancer drug.